Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Q&A: What the impressive durability of self-expanding TAVR valves means for patient care, shared decision-making

Sponsored by Medtronic

Updates about transcatheter aortic valve replacement (TAVR) are always big news, but the new five-year data from the CoreValve™ US Pivotal and SURTAVI trials came as a welcome surprise to many cardiologists. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Earlier interventions may boost survival when TAVR patients experience a stroke

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

CT imaging showing the congenital heart defect of left heart hypoplastic syndrome.

VIDEO: Congenital heart imaging with cardiac CT

As the population of patients with adult congenital heart disease grows, they are presenting to adult cardiology clinics and being imaged with CT. Many also do not have access or cannot be imaged by MRI, said Renee Bullock-Palmer, MD.

The Medtronic Intrepid transcatheter mitral valve replacement (TMVR) system performed well in two studies presendted at TCT 2022. #TCT #TCT22 #TCT2022 #TMVR

Intrepid transcatheter mitral valve pilot study shows positive 3-year outcomes

New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Regulatory Roundup: FDA clears AI model for RV/LV ratios, approves calcium-blocking TAVR valve and much more

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

The tricuspid valve anatomy is ofrten complicated for transcatheter structural heart interventions (TTVR) by the placement of pacemaker or ICD leads.

VIDEO: Addressing tricuspid valve regurgitation with new transcatheter interventions 

Joao Cavalcante, MD, of the Minneapolis Heart Institute, discusses new structural heart interventions to treat tricuspid valve regurgitation.

Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.

MitraClip and TriClip TEER devices continue to show positive results

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

Medtronic launches Evolut FX TAVR system aortic stenosis

Medtronic launches Evolut FX TAVR system for severe aortic stenosis

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.